Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients

CANDER, SONER; ÖZ GÜL, ÖZEN; Dizdar, Oguzhan; Koca, Nizameddin; Aydin, Taner; SARANDÖL, EMRE; ERSOY, CANAN

doi:10.1089/met.2017.0005

Assessing the Impact of Insulin Glargine and Detemir Treatment to Serum Total IGF1 Levels in the Insulin-Naive Type 2 Diabetic Patients

Copy For Citation

CANDER S., ÖZ GÜL Ö., Dizdar O. S., Koca N., Aydin T., SARANDÖL E., ...More

METABOLIC SYNDROME AND RELATED DISORDERS, vol.15, no.5, pp.220-225, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 15 Issue: 5
Publication Date: 2017
Doi Number: 10.1089/met.2017.0005
Journal Name: METABOLIC SYNDROME AND RELATED DISORDERS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.220-225
Bursa Uludag University Affiliated: Yes

Abstract

Aim: The mitogenic potential of analog insulins due to their different insulin-like growth factor-1 (IGF1) receptor affinity is a situation that causes concern related to cancer risk. We aimed to examine the changes in the serum IGF1 levels formed by insulin glargine and detemir in the insulin-naive type 2 diabetic patients.